The engines have fired up at last for MDX. ( BPRG ) At long last they are being recognised for the force they will become over the next two years. On the cusp of disclosing huge revenue-earning deals with Global pharmacists. These have been hinted at as being unrolled before the years end, but may be in the next days.You still have time to get in at a bargain-basement price before the SP takes off for real shortly.

bought some some MDX at 71p this morning...looking like a serious offer now :-)
Meldex International PLC
16 January 2008


16 January 2008

Meldex International plc

('Meldex' or the 'Company')

Appointment of Adviser

Further to the recent announcement regarding an approach which may or may not
lead to an offer for the Company, the Board of Meldex has appointed Houlihan
Lokey as its financial adviser, effective immediately, to advise it with respect
to its strategic options for the business.

Nomura Code Securities will continue to act as the nominated adviser and broker.

For further information:

Meldex International plc Tel. + 44 (0)20 7098 9880
Richard Trevillion, CEO
Steve Martin, CDO
Hiral Patel, CFO

Houlihan Lokey Tel. + 44 (0)20 7839 3355
Brian McKay
Simon Raynor

Nomura Code Securities Limited Tel. +44 (0)20 7776 1200
Richard Potts
Aasim Qureshi

Corfin Communications Tel. + 44 (0)20 7977 0020
Martin Sutton
Harry Chathli


About Meldex International plc

Meldex International plc is an innovative specialty pharmaceutical and OTC
product company. Listed on London's AIM in May 2003, the Company has over 80
patents granted or in application within 24 patent families and has product
development agreements and strategic alliances with several global healthcare
companies. Meldex has acquired sales and marketing resources within Europe and
the US as a launch mechanism for its own pharmaceutical products. Meldex
acquired the Melbrosin business in June 2007 for a consideration of up to 35m.
Melbrosin's focus is on consumer over the counter health care products based on
substances of natural and plant origin which are developed into consumer
orientated brands and then scaled, produced and distributed by Melbrosin. The
Melbrosin business complements the prescription pharmaceutical sales and
marketing business created and expanded in 2006.

The business continues to develop innovative delivery mechanisms enhancing both
its own product range and those of selected partners using its proprietary
XGELTM polymer technology. For further information please go to

www.meldexinternational.com


About Houlihan Lokey

Houlihan Lokey, an international investment bank, provides a wide range of
services, including mergers and acquisitions ('M&A'), financing and certain
other financial advisory services. In 2006, Houlihan Lokey ranked as the No.1
M&A adviser for U.S. transactions under $1 billion, according to Thomson
Financial. Established in 1970, the firm has 800 employees in 13 offices in the
United States, Europe and Asia. It annually serves more than 1,000 clients
ranging from closely held companies to Global 500 corporations. For more
information, visit
www.HL.com

same here 1 lot this morning and another after the news - this is gonna double from here and more - news will get through to the masses through the press no doubt as its just been seen by those following closely today.

Also we have the trading statement this month - not long to go!

I'm a buyer..topping up!

Who ia ramping this share?

Be careful and try an value the company before you buy!

Fred...not ramping just stating that we are buying....MDX is one of the few co's to go up today and you have to go with the trend :-)
I sold shares that might go down today after looking at the state of US market and bought more MDX with some of it...I have to say I have a lot of cash at the mo hoping to buy back the same shares lower.

Fred1new - read the RNS's and you will realise what is happening.

2 takeout my view - good luck all!

2 a minimum i would have thought, as with the trading update, and future 2008 profits, MDx will be worth 2 a share without a takeover. 2.50 minimum.
I just hope it is a big Pharma and not BM

could be right - it will be valued on current assets and potential which is immense.

Xgel in itself is going to be a winner long term. Just look what can be done with it.
Bar codes,Logos, prevent fake drugs, Rapid dissolve etc etc.

What about 30 a share?


Seems a good guess.



Place your stop losses!!!!

Thats better Fred looks like you have woken up to reality eventually!!

I heard 100 a share off a friend of a friend I met in the pub.

Sounds like the Klondike gold rush............there's tons of the stuff in them thar mountains...yeeeehaaaaaa!!!

Hon, I have a large holding of MDX having bought and sold numerous times over the last 4years.

But as Dil suggests, I feel the rampers are congregating again!

120p would do me

Dil, not an impertinent question........I hope, but are you the same Dil who used to post when it was BioP on Nasdaq?

The trading statement due this month is more important than a "potential" bid which may not materialise.

same here scot ,my take is 1.50 however, because at 90p+ the company said they saw no reason for the fall when it fell below 90p so I think a premium would be around 1.50 - just my view. Although the strong trading statement as stated in one of the previous RNS's could move this takeout to 1.75p.